title: Three new high-prevalence antigens in the Cromer blood group system.
abstract: BACKGROUND
  The Cromer blood group system consists of nine high-prevalence and three low-prevalence antigens carried on decay-accelerating factor (DAF). This report describes three new Cromer high-prevalence antigens, named ZENA, CROV, and CRAM.
  
  
  METHODS
  Sequence analyses were performed on DNA from three probands whose serum samples each contained an alloantibody to a high-prevalence antigen in the Cromer blood group system. Polymerase chain reaction-restriction fragment length polymorphism analysis to detect the mutation encoding the CROV- phenotype was performed on 100 Croatian donors. To map the respective epitopes, DAF deletion mutants were tested by immunoblotting with eluates containing the antibodies.
  
  
  RESULTS
  In each proband, sequence analysis revealed a single-nucleotide substitution in DAF: ZENA, 726T>G mutation, predicted change His242Gln; CROV, 466G>A mutation, predicted change Glu156Lys; and CRAM, 740A>G mutation, predicted change Gln247Arg. By analysis of DAF deletion mutants, the CROV antigenic determinant mapped to the complement control protein (CCP) domain 2, which is encoded by exon 3, whereas ZENA and CRAM mapped to CCP4, which is encoded by exon 6.
  
  
  CONCLUSIONS
  This study describes three novel high-prevalence antigens in the Cromer blood group system each characterized by a predicted single-amino-acid substitution. The antigens have been assigned the following International Society of Blood Transfusion (ISBT) numbers: ZENA is CROM13, CROV is CROM14, and CRAM is CROM15.
authors.affiliation: Laboratory of Immunochemistry and the Laboratory of Immunohematology, New York Blood Center, New York, New York, USA.
authors.forename: Kim
authors.initials: K
authors.lastname: Hue-Roye
authors.forename: Christine
authors.initials: C
authors.lastname: Lomas-Francis
authors.forename: Larisa
authors.initials: L
authors.lastname: Belaygorod
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Lublin
authors.forename: Janet
authors.initials: J
authors.lastname: Barnes
authors.forename: Amy
authors.initials: A
authors.lastname: Chung
authors.forename: Karen
authors.initials: K
authors.lastname: Fung-Kee-Fung
authors.forename: Jeff
authors.initials: J
authors.lastname: Kinney
authors.forename: Ronit
authors.initials: R
authors.lastname: Goldman-Lavi
authors.forename: Vered
authors.initials: V
authors.lastname: Yahalom
authors.forename: Joyce
authors.initials: J
authors.lastname: Poole
authors.forename: Zdravko
authors.initials: Z
authors.lastname: Ivankovic
authors.forename: Denden
authors.initials: D
authors.lastname: Alcantara
authors.forename: Marija
authors.initials: M
authors.lastname: Bekavac
authors.forename: Branka Golubic
authors.initials: BG
authors.lastname: Cepulic
authors.forename: Randall W
authors.initials: RW
authors.lastname: Velliquette
authors.forename: Richard
authors.initials: R
authors.lastname: Mason
authors.forename: Marion E
authors.initials: ME
authors.lastname: Reid
mesh_terms: D000818:Animals; D001483:Base Sequence; D001789:Blood Group Antigens / Q000032:analysis / Q000145:classification* / Q000235:genetics* / Q000276:immunology; D018958:CD55 Antigens / Q000235:genetics; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D018076:DNA, Complementary / Q000235:genetics; D005091:Exons / Q000235:genetics; D006801:Humans; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D017422:Sequence Analysis, DNA; D017384:Sequence Deletion / Q000235:genetics
chemical_list: D001789:Blood Group Antigens; D018958:CD55 Antigens; D018076:DNA, Complementary